18F-THK5351

**[18F]THK-5351** is a novel quinoline-derived radiopharmaceutical developed as a positron emission tomography (PET) imaging agent for the detection of tau pathology in the brain. It demonstrates high binding selectivity and affinity for neurofibrillary tangles composed of paired helical filaments (PHFs) of tau protein, which are characteristic of Alzheimer's disease and other tauopathies. Compared to earlier tracers like 18F-THK5117, it exhibits improved pharmacokinetics with faster kinetics, higher contrast in PET imaging, and lower retention in subcortical white matter. The tracer has been shown to correlate with the amount of tau deposits in human brain samples and can also detect reactive astrogliosis associated with neurodegenerative changes. Originally discovered by Tohoku University and further developed by GE Healthcare along with Samsung Medical Center and Asan Medical Center, [18F]THK-5351 is primarily used for diagnostic purposes to aid early detection and monitoring of Alzheimer's disease progression[5][3][2][6].

Brand names

FluoroTau

Other names

18F-THK5351THK-5351THK5351THK 5351[18F]THK-5351